Global Relapsed Acute Myeloid Leukemia Drug Market Growth 2022-2028

1.1 Market Introduction

1.2 Years Considered

1.3 Research Objectives

1.4 Market Research Methodology

1.5 Research Process and Data Source

1.6 Economic Indicators

1.7 Currency Considered

2 Executive Summary

2.1 World Market Overview

2.1.1 Global Relapsed Acute Myeloid Leukemia Drug Annual Sales 2017-2028

2.1.2 World Current & Future Analysis for Relapsed Acute Myeloid Leukemia Drug by Geographic Region, 2017, 2022 & 2028

2.1.3 World Current & Future Analysis for Relapsed Acute Myeloid Leukemia Drug by Country/Region, 2017, 2022 & 2028

2.2 Relapsed Acute Myeloid Leukemia Drug Segment by Type

2.2.1 aNK Program

2.2.2 AT-9283

2.2.3 BI-836858

2.2.4 Binimetinib

2.2.5 BL-8040

2.2.6 Others

2.3 Relapsed Acute Myeloid Leukemia Drug Sales by Type

2.3.1 Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2017-2022)

2.3.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue and Market Share by Type (2017-2022)

2.3.3 Global Relapsed Acute Myeloid Leukemia Drug Sale Price by Type (2017-2022)

2.4 Relapsed Acute Myeloid Leukemia Drug Segment by Application

2.4.1 Clinic

2.4.2 Hospital

2.4.3 Others

2.5 Relapsed Acute Myeloid Leukemia Drug Sales by Application

2.5.1 Global Relapsed Acute Myeloid Leukemia Drug Sale Market Share by Application (2017-2022)

2.5.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue and Market Share by Application (2017-2022)

2.5.3 Global Relapsed Acute Myeloid Leukemia Drug Sale Price by Application (2017-2022)

3 Global Relapsed Acute Myeloid Leukemia Drug by Company

3.1 Global Relapsed Acute Myeloid Leukemia Drug Breakdown Data by Company

3.1.1 Global Relapsed Acute Myeloid Leukemia Drug Annual Sales by Company (2020-2022)

3.1.2 Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Company (2020-2022)

3.2 Global Relapsed Acute Myeloid Leukemia Drug Annual Revenue by Company (2020-2022)

3.2.1 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Company (2020-2022)

3.2.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Company (2020-2022)

3.3 Global Relapsed Acute Myeloid Leukemia Drug Sale Price by Company

3.4 Key Manufacturers Relapsed Acute Myeloid Leukemia Drug Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Relapsed Acute Myeloid Leukemia Drug Product Location Distribution

3.4.2 Players Relapsed Acute Myeloid Leukemia Drug Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 World Historic Review for Relapsed Acute Myeloid Leukemia Drug by Geographic Region

4.1 World Historic Relapsed Acute Myeloid Leukemia Drug Market Size by Geographic Region (2017-2022)

4.1.1 Global Relapsed Acute Myeloid Leukemia Drug Annual Sales by Geographic Region (2017-2022)

4.1.2 Global Relapsed Acute Myeloid Leukemia Drug Annual Revenue by Geographic Region

4.2 World Historic Relapsed Acute Myeloid Leukemia Drug Market Size by Country/Region (2017-2022)

4.2.1 Global Relapsed Acute Myeloid Leukemia Drug Annual Sales by Country/Region (2017-2022)

4.2.2 Global Relapsed Acute Myeloid Leukemia Drug Annual Revenue by Country/Region

4.3 Americas Relapsed Acute Myeloid Leukemia Drug Sales Growth

4.4 APAC Relapsed Acute Myeloid Leukemia Drug Sales Growth

4.5 Europe Relapsed Acute Myeloid Leukemia Drug Sales Growth

4.6 Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales Growth

5 Americas

5.1 Americas Relapsed Acute Myeloid Leukemia Drug Sales by Country

5.1.1 Americas Relapsed Acute Myeloid Leukemia Drug Sales by Country (2017-2022)

5.1.2 Americas Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2017-2022)

5.2 Americas Relapsed Acute Myeloid Leukemia Drug Sales by Type

5.3 Americas Relapsed Acute Myeloid Leukemia Drug Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Relapsed Acute Myeloid Leukemia Drug Sales by Region

6.1.1 APAC Relapsed Acute Myeloid Leukemia Drug Sales by Region (2017-2022)

6.1.2 APAC Relapsed Acute Myeloid Leukemia Drug Revenue by Region (2017-2022)

6.2 APAC Relapsed Acute Myeloid Leukemia Drug Sales by Type

6.3 APAC Relapsed Acute Myeloid Leukemia Drug Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 Europe

7.1 Europe Relapsed Acute Myeloid Leukemia Drug by Country

7.1.1 Europe Relapsed Acute Myeloid Leukemia Drug Sales by Country (2017-2022)

7.1.2 Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2017-2022)

7.2 Europe Relapsed Acute Myeloid Leukemia Drug Sales by Type

7.3 Europe Relapsed Acute Myeloid Leukemia Drug Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 Middle East & Africa

8.1 Middle East & Africa Relapsed Acute Myeloid Leukemia Drug by Country

8.1.1 Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales by Country (2017-2022)

8.1.2 Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2017-2022)

8.2 Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales by Type

8.3 Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 Market Drivers, Challenges and Trends

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 Manufacturing Cost Structure Analysis

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Relapsed Acute Myeloid Leukemia Drug

10.3 Manufacturing Process Analysis of Relapsed Acute Myeloid Leukemia Drug

10.4 Industry Chain Structure of Relapsed Acute Myeloid Leukemia Drug

11 Marketing, Distributors and Customer

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Relapsed Acute Myeloid Leukemia Drug Distributors

11.3 Relapsed Acute Myeloid Leukemia Drug Customer

12 World Forecast Review for Relapsed Acute Myeloid Leukemia Drug by Geographic Region

12.1 Global Relapsed Acute Myeloid Leukemia Drug Market Size Forecast by Region

12.1.1 Global Relapsed Acute Myeloid Leukemia Drug Forecast by Region (2023-2028)

12.1.2 Global Relapsed Acute Myeloid Leukemia Drug Annual Revenue Forecast by Region (2023-2028)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Relapsed Acute Myeloid Leukemia Drug Forecast by Type

12.7 Global Relapsed Acute Myeloid Leukemia Drug Forecast by Application

13 Key Players Analysis

13.1 4SC AG

13.1.1 4SC AG Company Information

13.1.2 4SC AG Relapsed Acute Myeloid Leukemia Drug Product Offered

13.1.3 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.1.4 4SC AG Main Business Overview

13.1.5 4SC AG Latest Developments

13.2 AbbVie Inc.

13.2.1 AbbVie Inc. Company Information

13.2.2 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Product Offered

13.2.3 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.2.4 AbbVie Inc. Main Business Overview

13.2.5 AbbVie Inc. Latest Developments

13.3 Actinium Pharmaceuticals, Inc.

13.3.1 Actinium Pharmaceuticals, Inc. Company Information

13.3.2 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Offered

13.3.3 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.3.4 Actinium Pharmaceuticals, Inc. Main Business Overview

13.3.5 Actinium Pharmaceuticals, Inc. Latest Developments

13.4 Agios Pharmaceuticals, Inc.

13.4.1 Agios Pharmaceuticals, Inc. Company Information

13.4.2 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Offered

13.4.3 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.4.4 Agios Pharmaceuticals, Inc. Main Business Overview

13.4.5 Agios Pharmaceuticals, Inc. Latest Developments

13.5 Amgen Inc.

13.5.1 Amgen Inc. Company Information

13.5.2 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Product Offered

13.5.3 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.5.4 Amgen Inc. Main Business Overview

13.5.5 Amgen Inc. Latest Developments

13.6 Arog Pharmaceuticals, Inc.

13.6.1 Arog Pharmaceuticals, Inc. Company Information

13.6.2 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Offered

13.6.3 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.6.4 Arog Pharmaceuticals, Inc. Main Business Overview

13.6.5 Arog Pharmaceuticals, Inc. Latest Developments

13.7 Array BioPharma Inc.

13.7.1 Array BioPharma Inc. Company Information

13.7.2 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Offered

13.7.3 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.7.4 Array BioPharma Inc. Main Business Overview

13.7.5 Array BioPharma Inc. Latest Developments

13.8 Astellas Pharma Inc.

13.8.1 Astellas Pharma Inc. Company Information

13.8.2 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Offered

13.8.3 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.8.4 Astellas Pharma Inc. Main Business Overview

13.8.5 Astellas Pharma Inc. Latest Developments

13.9 Astex Pharmaceuticals, Inc.

13.9.1 Astex Pharmaceuticals, Inc. Company Information

13.9.2 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Offered

13.9.3 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.9.4 Astex Pharmaceuticals, Inc. Main Business Overview

13.9.5 Astex Pharmaceuticals, Inc. Latest Developments

13.10 AstraZeneca Plc

13.10.1 AstraZeneca Plc Company Information

13.10.2 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Product Offered

13.10.3 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.10.4 AstraZeneca Plc Main Business Overview

13.10.5 AstraZeneca Plc Latest Developments

13.11 AVEO Pharmaceuticals, Inc.

13.11.1 AVEO Pharmaceuticals, Inc. Company Information

13.11.2 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Offered

13.11.3 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.11.4 AVEO Pharmaceuticals, Inc. Main Business Overview

13.11.5 AVEO Pharmaceuticals, Inc. Latest Developments

13.12 BioLineRx, Ltd.

13.12.1 BioLineRx, Ltd. Company Information

13.12.2 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Product Offered

13.12.3 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.12.4 BioLineRx, Ltd. Main Business Overview

13.12.5 BioLineRx, Ltd. Latest Developments

13.13 Boehringer Ingelheim GmbH

13.13.1 Boehringer Ingelheim GmbH Company Information

13.13.2 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Product Offered

13.13.3 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.13.4 Boehringer Ingelheim GmbH Main Business Overview

13.13.5 Boehringer Ingelheim GmbH Latest Developments

13.14 Boston Biomedical, Inc.

13.14.1 Boston Biomedical, Inc. Company Information

13.14.2 Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Product Offered

13.14.3 Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.14.4 Boston Biomedical, Inc. Main Business Overview

13.14.5 Boston Biomedical, Inc. Latest Developments

13.15 Bristol-Myers Squibb Company

13.15.1 Bristol-Myers Squibb Company Company Information

13.15.2 Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Product Offered

13.15.3 Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.15.4 Bristol-Myers Squibb Company Main Business Overview

13.15.5 Bristol-Myers Squibb Company Latest Developments

13.16 Calithera Biosciences, Inc.

13.16.1 Calithera Biosciences, Inc. Company Information

13.16.2 Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Product Offered

13.16.3 Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.16.4 Calithera Biosciences, Inc. Main Business Overview

13.16.5 Calithera Biosciences, Inc. Latest Developments

13.17 Celgene Corporation

13.17.1 Celgene Corporation Company Information

13.17.2 Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Product Offered

13.17.3 Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.17.4 Celgene Corporation Main Business Overview

13.17.5 Celgene Corporation Latest Developments

13.18 Cornerstone Pharmaceuticals, Inc.

13.18.1 Cornerstone Pharmaceuticals, Inc. Company Information

13.18.2 Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Offered

13.18.3 Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.18.4 Cornerstone Pharmaceuticals, Inc. Main Business Overview

13.18.5 Cornerstone Pharmaceuticals, Inc. Latest Developments

13.19 CTI BioPharma Corp.

13.19.1 CTI BioPharma Corp. Company Information

13.19.2 CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Product Offered

13.19.3 CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2020-2022)

13.19.4 CTI BioPharma Corp. Main Business Overview

13.19.5 CTI BioPharma Corp. Latest Developments

14 Research Findings and Conclusion

Table 1. Relapsed Acute Myeloid Leukemia Drug Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)

Table 2. Relapsed Acute Myeloid Leukemia Drug Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)

Table 3. Major Players of aNK Program

Table 4. Major Players of AT-9283

Table 5. Major Players of BI-836858

Table 6. Major Players of Binimetinib

Table 7. Major Players of BL-8040

Table 8. Major Players of Others

Table 9. Global Relapsed Acute Myeloid Leukemia Drug Sales by Type (2017-2022) & (K Pcs)

Table 10. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2017-2022)

Table 11. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2017-2022) & ($ million)

Table 12. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Type (2017-2022)

Table 13. Global Relapsed Acute Myeloid Leukemia Drug Sale Price by Type (2017-2022) & (USD/Pcs)

Table 14. Global Relapsed Acute Myeloid Leukemia Drug Sales by Application (2017-2022) & (K Pcs)

Table 15. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2017-2022)

Table 16. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2017-2022)

Table 17. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Application (2017-2022)

Table 18. Global Relapsed Acute Myeloid Leukemia Drug Sale Price by Application (2017-2022) & (USD/Pcs)

Table 19. Global Relapsed Acute Myeloid Leukemia Drug Sales by Company (2020-2022) & (K Pcs)

Table 20. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Company (2020-2022)

Table 21. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Company (2020-2022) ($ Millions)

Table 22. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Company (2020-2022)

Table 23. Global Relapsed Acute Myeloid Leukemia Drug Sale Price by Company (2020-2022) & (USD/Pcs)

Table 24. Key Manufacturers Relapsed Acute Myeloid Leukemia Drug Producing Area Distribution and Sales Area

Table 25. Players Relapsed Acute Myeloid Leukemia Drug Products Offered

Table 26. Relapsed Acute Myeloid Leukemia Drug Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

Table 27. New Products and Potential Entrants

Table 28. Mergers & Acquisitions, Expansion

Table 29. Global Relapsed Acute Myeloid Leukemia Drug Sales by Geographic Region (2017-2022) & (K Pcs)

Table 30. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share Geographic Region (2017-2022)

Table 31. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Geographic Region (2017-2022) & ($ millions)

Table 32. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Geographic Region (2017-2022)

Table 33. Global Relapsed Acute Myeloid Leukemia Drug Sales by Country/Region (2017-2022) & (K Pcs)

Table 34. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Country/Region (2017-2022)

Table 35. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Country/Region (2017-2022) & ($ millions)

Table 36. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Country/Region (2017-2022)

Table 37. Americas Relapsed Acute Myeloid Leukemia Drug Sales by Country (2017-2022) & (K Pcs)

Table 38. Americas Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Country (2017-2022)

Table 39. Americas Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2017-2022) & ($ Millions)

Table 40. Americas Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Country (2017-2022)

Table 41. Americas Relapsed Acute Myeloid Leukemia Drug Sales by Type (2017-2022) & (K Pcs)

Table 42. Americas Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2017-2022)

Table 43. Americas Relapsed Acute Myeloid Leukemia Drug Sales by Application (2017-2022) & (K Pcs)

Table 44. Americas Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2017-2022)

Table 45. APAC Relapsed Acute Myeloid Leukemia Drug Sales by Region (2017-2022) & (K Pcs)

Table 46. APAC Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Region (2017-2022)

Table 47. APAC Relapsed Acute Myeloid Leukemia Drug Revenue by Region (2017-2022) & ($ Millions)

Table 48. APAC Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Region (2017-2022)

Table 49. APAC Relapsed Acute Myeloid Leukemia Drug Sales by Type (2017-2022) & (K Pcs)

Table 50. APAC Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2017-2022)

Table 51. APAC Relapsed Acute Myeloid Leukemia Drug Sales by Application (2017-2022) & (K Pcs)

Table 52. APAC Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2017-2022)

Table 53. Europe Relapsed Acute Myeloid Leukemia Drug Sales by Country (2017-2022) & (K Pcs)

Table 54. Europe Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Country (2017-2022)

Table 55. Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2017-2022) & ($ Millions)

Table 56. Europe Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Country (2017-2022)

Table 57. Europe Relapsed Acute Myeloid Leukemia Drug Sales by Type (2017-2022) & (K Pcs)

Table 58. Europe Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2017-2022)

Table 59. Europe Relapsed Acute Myeloid Leukemia Drug Sales by Application (2017-2022) & (K Pcs)

Table 60. Europe Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2017-2022)

Table 61. Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales by Country (2017-2022) & (K Pcs)

Table 62. Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Country (2017-2022)

Table 63. Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2017-2022) & ($ Millions)

Table 64. Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Country (2017-2022)

Table 65. Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales by Type (2017-2022) & (K Pcs)

Table 66. Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2017-2022)

Table 67. Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales by Application (2017-2022) & (K Pcs)

Table 68. Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2017-2022)

Table 69. Key Market Drivers & Growth Opportunities of Relapsed Acute Myeloid Leukemia Drug

Table 70. Key Market Challenges & Risks of Relapsed Acute Myeloid Leukemia Drug

Table 71. Key Industry Trends of Relapsed Acute Myeloid Leukemia Drug

Table 72. Relapsed Acute Myeloid Leukemia Drug Raw Material

Table 73. Key Suppliers of Raw Materials

Table 74. Relapsed Acute Myeloid Leukemia Drug Distributors List

Table 75. Relapsed Acute Myeloid Leukemia Drug Customer List

Table 76. Global Relapsed Acute Myeloid Leukemia Drug Sales Forecast by Region (2023-2028) & (K Pcs)

Table 77. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Forecast by Region

Table 78. Global Relapsed Acute Myeloid Leukemia Drug Revenue Forecast by Region (2023-2028) & ($ millions)

Table 79. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share Forecast by Region (2023-2028)

Table 80. Americas Relapsed Acute Myeloid Leukemia Drug Sales Forecast by Country (2023-2028) & (K Pcs)

Table 81. Americas Relapsed Acute Myeloid Leukemia Drug Revenue Forecast by Country (2023-2028) & ($ millions)

Table 82. APAC Relapsed Acute Myeloid Leukemia Drug Sales Forecast by Region (2023-2028) & (K Pcs)

Table 83. APAC Relapsed Acute Myeloid Leukemia Drug Revenue Forecast by Region (2023-2028) & ($ millions)

Table 84. Europe Relapsed Acute Myeloid Leukemia Drug Sales Forecast by Country (2023-2028) & (K Pcs)

Table 85. Europe Relapsed Acute Myeloid Leukemia Drug Revenue Forecast by Country (2023-2028) & ($ millions)

Table 86. Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales Forecast by Country (2023-2028) & (K Pcs)

Table 87. Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Revenue Forecast by Country (2023-2028) & ($ millions)

Table 88. Global Relapsed Acute Myeloid Leukemia Drug Sales Forecast by Type (2023-2028) & (K Pcs)

Table 89. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share Forecast by Type (2023-2028)

Table 90. Global Relapsed Acute Myeloid Leukemia Drug Revenue Forecast by Type (2023-2028) & ($ Millions)

Table 91. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share Forecast by Type (2023-2028)

Table 92. Global Relapsed Acute Myeloid Leukemia Drug Sales Forecast by Application (2023-2028) & (K Pcs)

Table 93. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share Forecast by Application (2023-2028)

Table 94. Global Relapsed Acute Myeloid Leukemia Drug Revenue Forecast by Application (2023-2028) & ($ Millions)

Table 95. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share Forecast by Application (2023-2028)

Table 96. 4SC AG Basic Information, Relapsed Acute Myeloid Leukemia Drug Manufacturing Base, Sales Area and Its Competitors

Table 97. 4SC AG Relapsed Acute Myeloid Leukemia Drug Product Offered

Table 98. 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 99. 4SC AG Main Business

Table 100. 4SC AG Latest Developments

Table 101. AbbVie Inc. Basic Information, Relapsed Acute Myeloid Leukemia Drug Manufacturing Base, Sales Area and Its Competitors

Table 102. AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Product Offered

Table 103. AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 104. AbbVie Inc. Main Business

Table 105. AbbVie Inc. Latest Developments

Table 106. Actinium Pharmaceuticals, Inc. Basic Information, Relapsed Acute Myeloid Leukemia Drug Manufacturing Base, Sales Area and Its Competitors

Table 107. Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Offered

Table 108. Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 109. Actinium Pharmaceuticals, Inc. Main Business

Table 110. Actinium Pharmaceuticals, Inc. Latest Developments

Table 111. Agios Pharmaceuticals, Inc. Basic Information, Relapsed Acute Myeloid Leukemia Drug Manufacturing Base, Sales Area and Its Competitors

Table 112. Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Offered

Table 113. Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 114. Agios Pharmaceuticals, Inc. Main Business

Table 115. Agios Pharmaceuticals, Inc. Latest Developments

Table 116. Amgen Inc. Basic Information, Relapsed Acute Myeloid Leukemia Drug Manufacturing Base, Sales Area and Its Competitors

Table 117. Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Product Offered

Table 118. Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 119. Amgen Inc. Main Business

Table 120. Amgen Inc. Latest Developments

Table 121. Arog Pharmaceuticals, Inc. Basic Information, Relapsed Acute Myeloid Leukemia Drug Manufacturing Base, Sales Area and Its Competitors

Table 122. Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Offered

Table 123. Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 124. Arog Pharmaceuticals, Inc. Main Business

Table 125. Arog Pharmaceuticals, Inc. Latest Developments

Table 126. Array BioPharma Inc. Basic Information, Relapsed Acute Myeloid Leukemia Drug Manufacturing Base, Sales Area and Its Competitors

Table 127. Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Offered

Table 128. Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 129. Array BioPharma Inc. Main Business

Table 130. Array BioPharma Inc. Latest Developments

Table 131. Astellas Pharma Inc. Basic Information, Relapsed Acute Myeloid Leukemia Drug Manufacturing Base, Sales Area and Its Competitors

Table 132. Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Offered

Table 133. Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 134. Astellas Pharma Inc. Main Business

Table 135. Astellas Pharma Inc. Latest Developments

Table 136. Astex Pharmaceuticals, Inc. Basic Information, Relapsed Acute Myeloid Leukemia Drug Manufacturing Base, Sales Area and Its Competitors

Table 137. Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Offered

Table 138. Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 139. Astex Pharmaceuticals, Inc. Main Business

Table 140. Astex Pharmaceuticals, Inc. Latest Developments

Table 141. AstraZeneca Plc Basic Information, Relapsed Acute Myeloid Leukemia Drug Manufacturing Base, Sales Area and Its Competitors

Table 142. AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Product Offered

Table 143. AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 144. AstraZeneca Plc Main Business

Table 145. AstraZeneca Plc Latest Developments

Table 146. AVEO Pharmaceuticals, Inc. Basic Information, Relapsed Acute Myeloid Leukemia Drug Manufacturing Base, Sales Area and Its Competitors

Table 147. AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Offered

Table 148. AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 149. AVEO Pharmaceuticals, Inc. Main Business

Table 150. AVEO Pharmaceuticals, Inc. Latest Developments

Table 151. BioLineRx, Ltd. Basic Information, Relapsed Acute Myeloid Leukemia Drug Manufacturing Base, Sales Area and Its Competitors

Table 152. BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Product Offered

Table 153. BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 154. BioLineRx, Ltd. Main Business

Table 155. BioLineRx, Ltd. Latest Developments

Table 156. Boehringer Ingelheim GmbH Basic Information, Relapsed Acute Myeloid Leukemia Drug Manufacturing Base, Sales Area and Its Competitors

Table 157. Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Product Offered

Table 158. Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 159. Boehringer Ingelheim GmbH Main Business

Table 160. Boehringer Ingelheim GmbH Latest Developments

Table 161. Boston Biomedical, Inc. Basic Information, Relapsed Acute Myeloid Leukemia Drug Manufacturing Base, Sales Area and Its Competitors

Table 162. Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Product Offered

Table 163. Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 164. Boston Biomedical, Inc. Main Business

Table 165. Boston Biomedical, Inc. Latest Developments

Table 166. Bristol-Myers Squibb Company Basic Information, Relapsed Acute Myeloid Leukemia Drug Manufacturing Base, Sales Area and Its Competitors

Table 167. Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Product Offered

Table 168. Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 169. Bristol-Myers Squibb Company Main Business

Table 170. Bristol-Myers Squibb Company Latest Developments

Table 171. Calithera Biosciences, Inc. Basic Information, Relapsed Acute Myeloid Leukemia Drug Manufacturing Base, Sales Area and Its Competitors

Table 172. Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Product Offered

Table 173. Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 174. Calithera Biosciences, Inc. Main Business

Table 175. Calithera Biosciences, Inc. Latest Developments

Table 176. Celgene Corporation Basic Information, Relapsed Acute Myeloid Leukemia Drug Manufacturing Base, Sales Area and Its Competitors

Table 177. Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Product Offered

Table 178. Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 179. Celgene Corporation Main Business

Table 180. Celgene Corporation Latest Developments

Table 181. Cornerstone Pharmaceuticals, Inc. Basic Information, Relapsed Acute Myeloid Leukemia Drug Manufacturing Base, Sales Area and Its Competitors

Table 182. Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Offered

Table 183. Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 184. Cornerstone Pharmaceuticals, Inc. Main Business

Table 185. Cornerstone Pharmaceuticals, Inc. Latest Developments

Table 186. CTI BioPharma Corp. Basic Information, Relapsed Acute Myeloid Leukemia Drug Manufacturing Base, Sales Area and Its Competitors

Table 187. CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Product Offered

Table 188. CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2022)

Table 189. CTI BioPharma Corp. Main Business

Table 190. CTI BioPharma Corp. Latest Developments

List of Figures

Figure 1. Picture of Relapsed Acute Myeloid Leukemia Drug

Figure 2. Relapsed Acute Myeloid Leukemia Drug Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate 2017-2028 (K Pcs)

Figure 7. Global Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate 2017-2028 ($ Millions)

Figure 8. Relapsed Acute Myeloid Leukemia Drug Sales by Region (2021 & 2028) & ($ millions)

Figure 9. Product Picture of aNK Program

Figure 10. Product Picture of AT-9283

Figure 11. Product Picture of BI-836858

Figure 12. Product Picture of Binimetinib

Figure 13. Product Picture of BL-8040

Figure 14. Product Picture of Others

Figure 15. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type in 2021

Figure 16. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Type (2017-2022)

Figure 17. Relapsed Acute Myeloid Leukemia Drug Consumed in Clinic

Figure 18. Global Relapsed Acute Myeloid Leukemia Drug Market: Clinic (2017-2022) & (K Pcs)

Figure 19. Relapsed Acute Myeloid Leukemia Drug Consumed in Hospital

Figure 20. Global Relapsed Acute Myeloid Leukemia Drug Market: Hospital (2017-2022) & (K Pcs)

Figure 21. Relapsed Acute Myeloid Leukemia Drug Consumed in Others

Figure 22. Global Relapsed Acute Myeloid Leukemia Drug Market: Others (2017-2022) & (K Pcs)

Figure 23. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2017-2022)

Figure 24. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Application in 2021

Figure 25. Relapsed Acute Myeloid Leukemia Drug Revenue Market by Company in 2021 ($ Million)

Figure 26. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Company in 2021

Figure 27. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Geographic Region (2017-2022)

Figure 28. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Geographic Region in 2021

Figure 29. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Region (2017-2022)

Figure 30. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Country/Region in 2021

Figure 31. Americas Relapsed Acute Myeloid Leukemia Drug Sales 2017-2022 (K Pcs)

Figure 32. Americas Relapsed Acute Myeloid Leukemia Drug Revenue 2017-2022 ($ Millions)

Figure 33. APAC Relapsed Acute Myeloid Leukemia Drug Sales 2017-2022 (K Pcs)

Figure 34. APAC Relapsed Acute Myeloid Leukemia Drug Revenue 2017-2022 ($ Millions)

Figure 35. Europe Relapsed Acute Myeloid Leukemia Drug Sales 2017-2022 (K Pcs)

Figure 36. Europe Relapsed Acute Myeloid Leukemia Drug Revenue 2017-2022 ($ Millions)

Figure 37. Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales 2017-2022 (K Pcs)

Figure 38. Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Revenue 2017-2022 ($ Millions)

Figure 39. Americas Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Country in 2021

Figure 40. Americas Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Country in 2021

Figure 41. United States Relapsed Acute Myeloid Leukemia Drug Revenue Growth 2017-2022 ($ Millions)

Figure 42. Canada Relapsed Acute Myeloid Leukemia Drug Revenue Growth 2017-2022 ($ Millions)

Figure 43. Mexico Relapsed Acute Myeloid Leukemia Drug Revenue Growth 2017-2022 ($ Millions)

Figure 44. Brazil Relapsed Acute Myeloid Leukemia Drug Revenue Growth 2017-2022 ($ Millions)

Figure 45. APAC Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Region in 2021

Figure 46. APAC Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Regions in 2021

Figure 47. China Relapsed Acute Myeloid Leukemia Drug Revenue Growth 2017-2022 ($ Millions)

Figure 48. Japan Relapsed Acute Myeloid Leukemia Drug Revenue Growth 2017-2022 ($ Millions)

Figure 49. South Korea Relapsed Acute Myeloid Leukemia Drug Revenue Growth 2017-2022 ($ Millions)

Figure 50. Southeast Asia Relapsed Acute Myeloid Leukemia Drug Revenue Growth 2017-2022 ($ Millions)

Figure 51. India Relapsed Acute Myeloid Leukemia Drug Revenue Growth 2017-2022 ($ Millions)

Figure 52. Australia Relapsed Acute Myeloid Leukemia Drug Revenue Growth 2017-2022 ($ Millions)

Figure 53. Europe Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Country in 2021

Figure 54. Europe Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Country in 2021

Figure 55. Germany Relapsed Acute Myeloid Leukemia Drug Revenue Growth 2017-2022 ($ Millions)

Figure 56. France Relapsed Acute Myeloid Leukemia Drug Revenue Growth 2017-2022 ($ Millions)

Figure 57. UK Relapsed Acute Myeloid Leukemia Drug Revenue Growth 2017-2022 ($ Millions)

Figure 58. Italy Relapsed Acute Myeloid Leukemia Drug Revenue Growth 2017-2022 ($ Millions)

Figure 59. Russia Relapsed Acute Myeloid Leukemia Drug Revenue Growth 2017-2022 ($ Millions)

Figure 60. Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Country in 2021

Figure 61. Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Country in 2021

Figure 62. Egypt Relapsed Acute Myeloid Leukemia Drug Revenue Growth 2017-2022 ($ Millions)

Figure 63. South Africa Relapsed Acute Myeloid Leukemia Drug Revenue Growth 2017-2022 ($ Millions)

Figure 64. Israel Relapsed Acute Myeloid Leukemia Drug Revenue Growth 2017-2022 ($ Millions)

Figure 65. Turkey Relapsed Acute Myeloid Leukemia Drug Revenue Growth 2017-2022 ($ Millions)

Figure 66. GCC Country Relapsed Acute Myeloid Leukemia Drug Revenue Growth 2017-2022 ($ Millions)

Figure 67. Manufacturing Cost Structure Analysis of Relapsed Acute Myeloid Leukemia Drug in 2021

Figure 68. Manufacturing Process Analysis of Relapsed Acute Myeloid Leukemia Drug

Figure 69. Industry Chain Structure of Relapsed Acute Myeloid Leukemia Drug

Figure 70. Channels of Distribution

Figure 71. Distributors Profiles